Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors. Dr. Bumol is Executive Director of the recently established Allen Institute for Immunology and former longtime senior executive at Eli Lilly and Company. “Tom is an internationally recognized leader in drug discovery and development with a strong track record of commercially successful drugs,” stated Gregory A. Demopulos, M.D., chairman and chief exec

Full Story →